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Near infrared dye-labelled polymeric micro- and nanomaterials: in 
vivo imaging and evaluation of their local persistence 
Gracia Mendozaa,b†*, Isabel Ortiz de Solorzanoa,b,c†, Inmaculada Pintrea, Sara Garcia-Salinasa,b,c, 
Victor Sebastiana,b,c, Vanesa Andreua,b, Marina Gimenod, Manuel Arrueboa,b,c
The use of micro- and nanomaterials as carriers of therapeutic molecules can enhance the efficiency of treatments while 
avoiding side effects thanks to the development of controlled drug delivery systems. The binding of a dye to a drug or to a 
drug-carrier has opened up a wide range of possibilities for an effective in vivo optical tracing of drug biodistribution by 
using non-invasive real-time technologies prior to their potential use as therapeutic vectors. Here, we describe the 
fluorescent tagging of polymeric micro- and nanomaterials based on poly(lactic-co-glycolic) acid and on the 
thermoresponsive poly(N-isopropylacrylamide) with the fluorescent probe IR-820 which was chemically modified for its 
covalent coupling to the materials. The chemical modification of the dye and the polymers yielded micro- and 
nanoparticulated labelled-materials to be potentially used as drug depots of different therapeutic molecules. In vitro 
biological studies revealed their reduced cytotoxicity. A spatiotemporal in vivo micro- and nanoparticle tracking allowed 
the evaluation of the materials biodistribution showing their local persistence and high biocompatibility after pathological 
studies. These results underline the suitability of those materials for the local, sustained, not harmful and/or on-demand 
drug delivery and the remarkable importance of evaluating materials biodistribution and tissue persistence for their use as 
local drug depots.
Introduction 
To engineer improved drugs and carrier systems for the 
delivery of therapeutic compounds in the target tissue is one 
of the main challenges in present biomedicine. Oral absorption 
or intravenous (IV) drug administration produce a systemic 
distribution of the drug that can lead to unwanted side effects 
in non-pathological tissues. The development of site-specific or 
targeted therapies is closely linked to the profound knowledge 
of drug biodistribution in order to increase selectivity and 
decrease unwanted side effects. In this regard, the use of 
carriers, i.e., micro- and nanoparticles (NPs), has attracted 
increasing interest thanks to their ability to preserve 
therapeutic molecules from metabolism and to provide with 
site-specificity.1 
In order to deepen into in vivo drug biodistribution, the 
tracking of drug carriers has been widely studied by using 
radiotracers, obtaining the distribution of the drug carrier by 
liquid scintillation counting2 or by scintillating proximity assays 
based on immune recognition.3 However, the synthesis and 
manipulation of radiolabelled materials imply some 
occupational risks and the required resources are not always 
affordable; therefore, the search of safer and equally effective 
technologies represents an ongoing scientific task. Medical 
imaging encompasses techniques based on different physical 
or chemical approaches such as ultrasonography, 
elastography, molecular imaging or chemical shift imaging.4 
Imaging techniques are widely used in diagnosis, progression 
and treatment of different diseases in the medical field due to 
their outstanding role in the deeper understanding of in vivo 
molecular events.5 These techniques are classified in 
morphological (e.g., magnetic resonance imaging (MRI), 
computed tomography (CT)) and functional and molecular 
techniques (e.g., optical imaging, functional magnetic 
resonance imaging (fMRI), positron emission tomography 
(PET) and single-photon emission computerized tomography 
(SPECT)).6,7 Optical imaging allows the non-invasive real-time 
imaging of physiological events in living organisms using non-
ionizing radiation. It is based on the light emission by 
bioluminescence, in which takes part the enzyme luciferase 
and the substrate luciferin, or by fluorescence, that involves 
the absorption of light at a specific wavelength to emit light at 
a higher wavelength.6,8 Bioluminescence relies on the 
conversion of chemical energy into light and the detection of 
photons emitted by living cells or tissues though with the 
requirement of the expression of the enzyme luciferase, 
whereas fluorescence is supported on light absorption without 
the involvement of any endogenous molecule.8 Optical 
imaging techniques present advantages compared to other 
techniques, such as safer manipulation, reduced costs and a 
 
times in vivo up to 28 days after local administration, much 
longer than systemic administrations and preventing the non-
specific delivery of drugs and the subsequent side effects.32-35  
The aim of this work is to develop novel polymeric micro- and 
nanomaterials of different sizes dye-labelled with the NIR dye 
IR-820 to track their in vivo biodistribution and persistence 
after intramuscular (IM) and subcutaneous (SC) administration 
in nude mice. The chemical modification of the dye enabled 
the covalent attachment to the polymers as terminal groups to 
obtain stable and biocompatible materials for potential drug 
delivery applications allowing a simultaneous tracking of the 
drug carrier. The dye-labelled materials were physico-
chemically characterized and in vitro tested for their 
cytotoxicity. In vivo studies after IM and SC injection were 
carried out to test their persistence, biodistribution and tissue 
response.
Experimental section 
Supplementary materials and methods and any associated 
references are available in the Supplementary Material section. 
Synthesis and characterization of PLGA and PNIPAM dye-labelled 
materials 
Carbodiimide covalent labelled PLGA by the amino-modified IR820 
(PLGA-IR820-NH2), PLGA encapsulating the NIR dye (PLGA-IR820 
encapsulated) during the NP simple emulsion synthesis, tagged 
PNIPAM by the acidic-modified IR820 added during the polymer 
synthesis (PNIPAM-IR820-COOH) or after the NPs synthesis 
(PNIPAM-IR820-COOH post-synthesis) by covalent carbodiimide 
bond, labelled PNIPAM microgels by the fluorophore (PNIPAM-
IR820 microgels) through contact incubation and tagged PNIPAM 
microparticles (MPs) by IR820 (PNIPAM-IR820 microparticles) in the 
same way than microgels were synthesized and characterized as 
detailed in the Supplementary Material section. Briefly, NPs were 
synthesized by single emulsion while PNIPAM-IR820 MPs were 
prepared by microfluidic LED photopolymerization and PNIPAM-
IR820 microgels by precipitation polymerization in a batch reactor. 
Following the synthesis, IR-820 was either encapsulated within 
PLGA during the emulsion formation to render PLGA-IR820 
encapsulated or chemically modified to provide it with reactive 
functional groups to be bound to the different micro- or 
nanoparticles. PLGA-IR820-NH2, PNIPAM-IR820-COOH and PNIPAM-
IR820-COOH post-synthesis were fluorescently labelled by using 
carbodiimide coupling (EDC/NHS) of the modified dye and the 
corresponding NP. The modified dyes and the materials obtained 
were further characterized by UV-vis spectroscopy, scanning 
electron microscopy (SEM), Fourier transform infrared spectroscopy 
(FTIR), mass spectrometry and NMR spectroscopy. Transmittance 
studies were also carried out with the PNIPAM modified material in 
order to confirm the stability of its LCST. 
Biological studies 
The cytotoxicity of the labelled materials was studied at three 
essential levels: cell metabolism, cell cycle and endotoxin content.  
faster and more reliable response as they are not restricted to 
anatomical or physiological processes.5,9,10 Considering these 
advantages, the optical imaging technique called IVIS (in vivo 
imaging system) has emerged as a useful preclinical method 
for facilitating the diagnosis in different biomedical fields such 
as pharmacology, oncology or immunology.9  
In this regard, the development of safer and novel fluorescent 
organic dyes has yielded interesting derivatives which combine 
in the same molecule water solubility (e.g., mediated by 
functionalization), high quantum yield, reduced 
photobleaching and stability to enhance the molecule lifetime 
and to guarantee near infrared (NIR) emission with elevated 
signal-to-noise ratio.(11, 12) NIR dyes appear as useful tools for 
fluorescence detection and imaging due to their reduced light 
scattering and almost no interference regarding tissue 
autofluorescence.(13-15) Among them, only methylene blue and 
indocyanine green (ICG) are approved dyes by the Food and 
Drug Administration (FDA) as extrinsic fluorescent contrast 
agents.16 Methylene blue medical uses are much more 
restricted than ICG, which has been widely used in the 
evaluation of the hepatic and cardiac function and in 
ophthalmic angiography.(14, 16-18) However, it has been reported 
its low stability, slight in vitro toxicity (10 µM after 72 h of 
incubation) and quick liver clearance,19 pointing to the 
outstanding necessity of developing novel or even superior NIR 
dyes for biomedical imaging.  
IR-820 is a NIR dye with an improved in vitro and in vivo 
stability compared to ICG and the same optical properties.20 
Furthermore, its chemical modification to be anchored to 
polymers has been shown as a more effective approach than 
the use of the free fluorophore,21 highlighting its potential to 
allow an efficient tracking of in vivo drug carrier 
biodistribution.   
The biodegradable and biocompatible properties of polymeric 
micro- and nanomaterials make them very attractive to tune 
their lifetime and play an important role in the sustained or 
triggered release of drugs22 or even in the photodynamic 
treatment of cancer.(23-25) Poly(lactic-co-glycolic) acid (PLGA), a 
building polymer in many FDA-approved biomedical products, 
has been widely described as nanocarrier protecting NIR dyes 
from degradation.26-28 This fact, together with the well-known 
biocompatibility of PLGA for therapeutic approaches, points to 
the suitability of these systems for in vivo biomedical imaging. 
In fact, the successful loading of drugs and NIR dyes in PLGA 
nanosystems has been widely evaluated in in vivo tumour 
models.29,30 The thermoresponsive polymer polyN-
isopropylacrylamide (PNIPAM) shows the possibility to trigger 
the delivery of a drug in response to temperature changes. The 
increase in temperature above its lower critical solution 
temperature (LCST) produces the collapse of the polymer 
domains and the shrinkage of the particles.31 Furthermore, the 
need of long-term therapies in pathologies as diverse as 
cancer, cardiovascular affections or chronic pain, has produced 
the compelling development of sustained or triggerable 
release carriers or scaffolds in order to obtain the required 
drug release avoiding multiple administrations. These novel 
carriers based on PLGA and/or PNIPAM have shown release 
the quantification of endotoxin content in our materials prior to 
their in vivo application.  
The Endpoint Chromogenic LAL assay (QCL-1000) (Lonza, Belgium) 
was developed to quantify the endotoxin content in the different 
materials (1 mg/mL) according to the manufacturer’s indications. In 
brief, 50 µL of diluted samples (1:100 to 1:750 dilution in endotoxin-
free water) were dispensed in duplicate in each well of a microplate 
well. LAL reagent was then added and subsequently the plate was 
shaken and incubated (37 ºC, 10 min). Following incubation, pre-
warmed chromogenic substrate was added and the plate was again 
incubated (37 ºC, 6 min). Finally, the reaction was stopped (10% 
SDS solution) and absorbance read at 405 nm in a Synergy HT 
Microplate Reader (Biotek, US). The determination of the endotoxin 
levels in the samples was calculated as indicated by the 
manufacturer. 
In vivo studies 
All procedures were carried out under Project License 02/16 
approved by the Ethic Committee for Animal Experiments from the 
University of Zaragoza (Spain). The care and use of animals were 
performed accordingly with the Spanish Policy for Animal 
Protection RD53/2013, which meets the European Union Directive 
2010/63 on the protection of animals used for experimental and 
other scientific purposes.  
Five- to eight-week-old female BALB/c nu/nu mice (Janvier, France) 
were used for these studies. Mice were anesthetized with 5% 
isoflurane under oxygen flow of 1 L/min and maintained with a 2%. 
All animals received subcutaneous (SC; 200 µL) or intramuscular 
(IM; 20 µL) injections of the materials described above (1 mg/mL) 
diluted in saline solution (or saline solution in control animals) in 
order to evaluate the biodistribution and persistence of locally 
administered injections. Animals were examined daily with especial 
attention to the injection site.  
Our purpose was to target the key tissue avoiding systemic 
administration and to further investigate the differences between 
both administrations taking into account the different volumes 
administered as well as the different metabolic rates of both 
tissues. Thus, imaging analysis was developed at different time 
points up to 7 days when using IM administration and 14 days when 
using SC administration in an IVIS® Lumina Xenogen equipment and 
Living Image® software (Caliper, US). 
In addition, the persistence of IM and SC-administered not labelled 
PNIPAM MPs in tissue was also assayed in order to elucidate their 
long-term persistence and the possible damage to tissues after 30 
and 60 days p.i. PLGA NPs were not included in this study as it is 
widely known their tunable persistence depending on its 
monomeric composition and safety in vivo.33,38 As before, MPs were 
administered IM and SC at the same conditions stated above and 
animals were euthanized at 30 and 60 days p.i. 
Pathologic studies 
All animals were euthanized by cervical dislocation under 5% 
isoflurane anaesthesia under oxygen flow of 1 L/min 
(unconsciousness condition). A full post mortem procedure was 
carried out with special attention to the injection site 
(subcutaneous tissue, muscular tissue, inguinal and popliteal lymph 
nodes). These studies were performed to assess the safety and 
The studies regarding cell cultures were performed on five different 
cell lines after treatment for 48 h with the different materials 
prepared.  
Human dermal fibroblasts were obtained from Lonza (Belgium) and 
THP1 human monocytes from the American Type Culture Collection 
(ATCC, US). Human tumour cells U251MG and mouse mesenchymal 
stem cells (mMSCs) were kindly gifted by Dr Pilar Martín-Duque. 
Fibroblasts and U251MG cells were cultured in DMEM high glucose 
(Biowest, France) containing 2 mM L-glutamine and supplemented 
with 10% v/v fetal bovine serum (Gibco, UK) and 1% penicillin-
streptomycin-amphotericin B (Biowest, France). Monocytes were 
grown in RPMI 1640 (Biowest, France) containing 2 mM L-glutamine 
and supplemented with 10% v/v fetal bovine serum (Gibco, UK), 1% 
HEPES (Lonza, Belgium), 0.1% 2-mercaptoethanol 50 mM (Gibco, 
UK), 1% non-essential aminoacids, 1% sodium pyruvate 100 mM 
and 1% penicillin-streptomycin-amphotericin B (Biowest, France). 
The in vitro differentiation of monocytes to macrophages was 
performed by the addition of 1 µM phorbol 12-myristate 13-acetate 
(PMA) (Sigma Aldrich, US) to the cell culture medium for 72 h 
obtaining the characteristic adherent morphology of macrophages. 
mMSCs were cultured in DMEM-F12 (Biowest, France) 
supplemented with 1% glutamine (Gibco, UK), 10% FBS (Gibco, UK) 
and 1% penicillin-streptomycin-amphotericin B (Biowest, France). 
All cell types were cultured at 37 ºC and 5% CO2, except for mMSCs 
which were grown in hypoxia (3% O2).  
As previously mentioned, the materials tested were PLGA-IR820-
NH2, PLGA-IR820 encapsulated, PNIPAM-IR820-COOH, PNIPAM-
IR820-COOH post-synthesis, PNIPAM-IR820 microgels and PNIPAM-
IR820 MPs. The cell types described above were incubated with 
these materials for 48 h to study cell viability and cell cycle. 
Blue Cell Viability assay (Abnova) was used to evaluate the viability 
related to cell metabolism after incubation with the materials (0.1-2 
mg/mL) for 48 h. The reagent was added to the cells (10%) and after 
incubation (4 h, 37 ºC, 5% CO2), fluorescence was recorded 
(535/590 nm ex/em) in a Synergy HT Microplate Reader (Biotek, 
US). Control samples without cells were also run to evaluate a 
potential NP interference in the assay. Cell viability was calculated 
by interpolation of the emission data exerted by the treated 
samples and the control ones (control samples = 100% viability). 
The distribution of cell cycle phases was determined by flow 
cytometry. Cells were exposed for 48 h to materials (1 mg/mL), 
collected in PBS, fixed in 70% ice-cold ethanol and incubated at 4 ºC 
for 24 h. Then, DNA was stained by adding a solution of 50 µg/mL 
propidium iodide and 100 µg/mL RNase A in PBS. DNA content was 
analysed in a FACSARRAY BD equipment and cell cycle was 
determined by using the software MODIFIT 3.0 Verity. Negative 
controls were also run to compare the basal level of cell cycle to 
that obtained after materials treatment and control samples 
without cells were also analysed to test a potential NP interference 
with the methodology. 
Endotoxins or lipopolysaccharides (LPS) are bioactive heat-stable 
molecules present in the outer cell-wall of gram-negative bacteria. 
They can induce inflammation and immune response of the host 
organism or even sepsis.36,37 During the production and handling of 
micro- and nanomaterials, these materials can be contaminated 
with endotoxin with the subsequent health risks in a potential 
future application.37 Due to this potential concern, we performed 
The study of the absorbance and fluorescence of the dye-
functionalized polymers revealed similar optical performance 
compared to the not modified dye in terms of Stokes shift and 
stability. Table 1 summarizes the maximum absorbance and 
emission values for these polymeric dispersions. PLGA-IR820 
could only be measured in acetone because it is not soluble in 
methanol or water. For that reason, no comparison with the 
dyes could be exerted, as the dyes are insoluble in acetone. In 
the case of PNIPAM-IR820, the effect of the solvent is similar 
increasing the Stokes shift in water, being the value for this 
polymer the highest of all the measured samples. This fact 
indicates that the attachment of the dye to the polymer did 
not alter significantly the emission properties of the dye as its 
emission range still remained in the NIR region (750-950 nm). 
Considering that the NP size is an important factor for in vivo 
studies, we synthetized six different particles with a wide 
range of sizes in order to determine differences in their 
behaviour prior carrying out in vivo experimentation. IR820 
was internalized in the polymeric vectors by two approaches: 
1) Tagging the polymer with the dye and 2) Encapsulating the
dye in the polymeric matrix.  Size, morphology and loading
protocol of the different particles used in this study are
summarized in Figure 1. NPs based on PLGA-IR820-NH2, PLGA-
IR820 encapsulated, PNIPAM-IR820-COOH and PNIPAM-IR820-
COOH post synthesis were produced through a simple
emulsion-evaporation method assisted by ultrasound radiation
leading to NP sizes between 119 to 560 nm (Figure 1a-d).
Nevertheless, in order to study the in vivo animal response to
larger particles, PNIPAM microgels and MPs were loaded by
diffusion with IR-820 after three days contact in a solution of
the saturated fluorophore and subsequent purification (see
experimental details in the Supplementary Material section).
Their sizes were much larger than those displayed by the other
materials synthesized, exerting diameters higher than 600 nm
in the case of the microgels (Figure 1e) whereas MPs achieved
a mean size up to 439 µm (Figure 1f). After synthesis a
potential detachment of the dye from the corresponding
particles was discarded after evaluating the fluorescence of
the supernatants collected by incubating the particles in saline
media.
Table 1. Stokes shift of the polymers in different solvents. Data 
are presented in nm 
Sample Solvent λmax abs λmax em Stokes shift 
IR820 Methanol 819 838 19 
PLGA-IR820 Acetone 623 767 144 
PNIPAM-IR820 Methanol 664 780 116 
PNIPAM-IR820 Water 642 792 150 
biocompatibility of the synthetized materials at a local and systemic 
level, complementing the in vitro cell studies. Representative 
sections of the injection area and local lymph nodes, lung, heart, 
brain, liver, spleen, kidney and gastrointestinal organs were 
systematically collected. Tissues were fixed in 4% buffered 
paraformaldehyde and embedded in paraffin. Five-micron-thick 
tissue sections were obtained and stained with haematoxylin and 
eosin (HE). Masson's trichrome staining was applied to skin samples 
to better describe connective tissue reaction to the materials at the 
injection area. 
Results and discussion 
Synthesis and characterization of dye-labelled materials 
PLGA and PNIPAM micro- and nanoparticles (MPs and NPs) 
were labelled with the IR-820 dye through three different 
methodologies in order to obtain dye-labelled materials of 
different sizes for potential drug delivery approaches as depot 
devices: 1) Labelling the polymer prior and after particle 
formation, 2) Trapping the dye during the particle formation 
by emulsification and solvent evaporation, 3) Loading the dye 
after particle formation by diffusion. IR-820 was chemically 
modified with amine and carboxyl groups to enable a proper 
labelling of PLGA and PNIPAM and to prevent its detachment 
from the carrier. The chemically modified IR-820 and the 
labelled polymers were conveniently studied by NMR 
spectroscopy of 13C and 1H, Fourier transform infrared 
spectroscopy (FTIR) and mass spectrometry in order to 
determine their purity and their chemical and spectral stability 
(Figures S1-S4).  
Comparing the amino- and carboxy-functionalized dyes with 
plain IR-820 dissolved in methanol we observed that the IR-
820 derivatives exhibited a larger Stokes shift (difference 
between the excitation and emission wavelengths of the same 
electronic transition) compared to the unmodified IR-820 
(Figure S5). This ensures a better performance of the modified 
dyes since it reduces the chances of self-quenching. Thus the 
resulting dyes were more sensitive NIR fluorescent probes 
than the non-functionalized ones. When the solvent was 
changed to water, the fluorescence decreased for both IR-820 
and IR820-COOH (data not shown), in agreement with the 
previous literature39 that also reported in cyanine dyes lower 
values of quantum yield when using water as solvent.  
The characterization of modified polymers was carried out in 
order to evaluate their chemical and spectral properties as NIR 
fluorophores (Figures S3 and S4). However, in the case of 
PNIPAM, its thermoresponsive behaviour must be preserved 
after chemical modification. To ensure it, a transmittance 
curve of the chemically modified polymer was compared to 
the non-modified one, observing insignificant variations and 
exerting a transition temperature of around 36.5 ºC at 50% 
transmittance for both compounds (data not shown). 
Figure 1 SEM micrographs and loading scheme of the materials synthesized. a) PLGA-IR820 NPs produced by the emulsification-evaporation method. The 
dye was encapsulated during NPs formation; b) PLGA-IR820-NH2 produced by the emulsification-evaporation method. The polymer was tagged with the dye 
prior to NPs formation; c) PNIPAM-IR820-COOH produced by the emulsification-evaporation method. The polymer was tagged with the dye prior to NPs 
formation; d) PNIPAM-IR820-COOH post synthesis, produced by the emulsification-evaporation method. The polymer was tagged with the dye after NPs 
formation; e) PNIPAM-IR820 microgels, produced by a polymerization process. The dye was encapsulated after NPs formation; f) PNIPAM-IR820 
microparticles, produced by a polymerization-crosslinking process. The dye was encapsulated after NPs formation. Morphology and size of the particles are 
representative (n ≥ 500; Mean ± SD). 
concentration was also estimated on each carrier (Table S1) 
through quantification with the Living Image® software 
(Caliper, US). A clear correlation between these measured 
concentrations and the intensity of the in vivo signal was not 
observed, which is consistent with a higher efficiency related 
to their chemical modification to be anchored to the polymers 
and their interaction with the surrounding tissues. 
In vitro cytotoxicity studies 
The cytotoxic effects of the materials described above were 
analysed on human dermal fibroblasts, monocytes, 
macrophages, mMSCs and U251MG cells through the 
treatment of these cell lines with the different synthesized 
PNIPAM hydrogels tagged with IR820 have been previously 
developed following the same labelling methodology as ours 
by submerging hydrogels in an IR-820 solution, though using 
only one monomer (N-isopropylacrylamide) and reporting a 
low cloud point (~32 ºC), that is the temperature above which 
an aqueous solution becomes turbid due to its change in 
solubility (i.e., coil-to-globule transition), and higher gel sizes 
(millimetre range), which preclude their biomedical 
application.40 Our results clearly show the broad spectrum of 
sizes of our labelled materials to fulfil different requirements 
for screening the biodistribution and persistence of different 
materials widely used as drug delivery vectors. In order to 
complete the characterization of the different vectors, IR820 
materials for 48 h. The effects on cell metabolism were 
assessed by the Blue Cell Viability assay while cell cycle was 
analysed by flow cytometry. In addition, the endotoxin content 
of the synthetized materials was also tested to assure their 
safety for in vivo administration. According to the ISO 10993-5 
(Biological evaluation of medical devices: Tests for in vitro 
cytotoxicity)41 a reduction in viability larger than 30% is 
considered a cytotoxic effect. 
The treatment of the cell types assayed with increasing 
concentrations of PLGA and PNIPAM-IR820-COOH up to 2 
mg/mL did not involve a substantial decrease in cell viability in 
all cases (Figures 2a-c) showing viability percentages higher 
than 70% at a final concentration of 1 mg/mL. PNIPAM-IR820-
COOH post-synthesis (Figure 2d) exerted slightly higher toxic 
effects on the cell types tested at 2 mg/mL. However, cell 
viability was higher than 70% at a concentration of 1 mg/mL 
for macrophages, monocytes and U251MG cells. The effects of 
cell treatment with PNIPAM-IR820 microgels (Figure 2e) were 
found more cytotoxic at the highest concentration studied (2 
mg/mL) pointing to 1 mg/mL as the non-cytotoxic dose 
yielding viability percentages higher than 70% on fibroblasts 
and mMSCs. PNIPAM-IR820 MPs (Figure 2f) showed low 
cytotoxicity exerting viability percentages higher than 66% at 
concentrations up to 1 mg/mL.  
Furthermore, the viability of mMSCs treated with microgels 
and MPs was found higher than that obtained for control 
samples (Figures 2e and 2f). These results may be attributed to 
the polymeric nature, mechanical features and viscosity of 
those dispersions, mimicking the extracellular matrix (ECM), 
and the anchorage dependency of these cells to avoid 
apoptosis,42-44 together with the demonstrated higher viability 
and proliferation of mesenchymal stem cells seeded on 
PNIPAM gels compared to 2D cultures.45 Regarding these data,  
Figure 2 Cell viability of the dye-labelled materials on the five cell lines assayed after 48 h. a) PLGA-IR820 encapsulated; b) PLGA-IR820-NH2; c) 
PNIPAM-IR820-COOH; d) PNIPAM-IR820-COOH post synthesis; e) PNIPAM-IR820 microgels; f) PNIPAM-IR820 microparticles. The possible 
interferences of the labelled materials with the methodology or the reagent were evaluated and discarded. The red mark sets the 
biocompatilibity threshold percentage (70% viability). Control group (not treated cells) = 100% viability. Data are expressed as Mean ± SD (n = 5).  
1 mg/mL was considered as the subcytotoxic concentration for 
further studies. 
The effect of PLGA and PNIPAM at 1mg/mL on cell cycle after 
48 h of incubation is shown in Table S2. The addition of PLGA 
data explained in Table S1. In addition, at the end of the 
experiments and immediately after euthanasia, the main 
organs were ex vivo visualized by IVIS scanning to track the 
possible accumulation of the materials (data not shown) 
though no trace was observed, highlighting the local 
biodistribution and persistence of the administered materials. 
It should be also noted the high intensity of the signal in both 
types of administrations, pointing to the potential of our 
labelled materials for the study of micro- and nanoparticle 
biodistribution as well as for drug delivery taking into account 
the high biocompatibility of the dye-labelled materials 
described above. 
Pathologic studies 
At the necropsy, no animal showed macroscopic lesions 
compatible with inflammation, infection or degeneration at 
local or systemic levels. Microscopically, all animals injected 
with the different synthetized materials (PLGA-IR820 
encapsulated, PLGA-IR820-NH2, PNIPAM-IR820-COOH, 
PNIPAM-IR820-COOH post synthesis, PNIPAM-IR820 microgels 
and PNIPAM-IR820 microparticles) did not present any lesions 
at epidermis, dermis, subcutaneous tissue, musculature or 
local lymph nodes for both SC and IM administrations (Figure 
5). 
The group administered with non-labelled PNIPAM MPs used 
to test the persistence of MPs in tissue, showed foreign body 
reaction at the subcutaneous musculature at day 60 (Figure 6). 
This reaction was well circumscribed characterized by active 
fibroblasts forming a fibrous encapsulation of the eosinophilic 
amorphous material intermixed with moderate number of 
macrophages, foreign body giant cells and scarce neutrophils. 
The collagenous tissue and fibroblast encapsulation of the 
material was more evident using Masson's trichrome stain. 
The popliteal lymph node showed a moderate paracortical 
lymphocyte hyperplasia identified by increased lymphocyte 
density accompanied by increased paracortical area. No 
microscopic lesions were found in all remaining organs studied 
(brain, heart, kidney, liver, lung, spleen and gastrointestinal 
organs), denoting the lack of systemic toxicity by the 
synthetized materials. 
Drug site-specific biodistribution has become a main issue for 
the improvement of novel therapeutic strategies and a key 
aspect to efficiently engineer drug-delivery vectors. The 
imaging tracking of drug-carrier biodistribution is very relevant 
to identify the penetration and persistence of the carried drug 
in treated tissue avoiding biopsy.48,49 Furthermore, the 
development of new approaches to improve long-term 
therapies has entailed the use of sustained or controlled 
release nanocarriers, which are able to effectively 
and PNIPAM at the subcytotoxic dose did not involve an 
accentuated effect on cell-cycle phase distribution; hence DNA 
replication and cell division were not affected or halted by 
these treatments. The addition of PLGA to the cells barely 
displayed effects on cell cycle, only a slight decrease in G2 
phase in U251MG and fibroblasts and a reduced increase in G1 
phase in mMSCs were observed. 
PNIPAM exerted mild changes in cell-cycle phases being a little 
more accentuated for PNIPAM-IR820-COOH post-synthesis. 
The determination of endotoxin content with the Endpoint 
Chromogenic LAL assay did not reveal the presence of 
significant endotoxin concentrations. The measured values 
were much lower than 0.05 ng/mL (0.5 endotoxin unit 
(EU)/mL), the safe threshold established by the FDA.46 In 
addition, the materials and fluorophores assayed did not show 
any interference with the reagents or the developed 
techniques (data not shown).  
In conclusion, labelled PLGA and PNIPAM materials did not 
alter significantly cell metabolism or cell cycle on the cell lines 
tested at concentrations up to 1 mg/mL, and did not display 
potentially harmful endotoxin levels for in vivo administration, 
showing their suitability for in vivo imaging and potential drug 
delivery applications.  
In vivo imaging and biodistribution of dye-labelled materials 
IVIS scanning was used to visualize material biodistribution at 
different time points after IM and SC administration in nude 
mice. Figures 3 and 4 displayed the results obtained from 
these in vivo imaging studies. IM administered animals (Figure 
3) were visualized until 7 days post-injection (p.i.) while SC 
administered mice (Figure 4) were analysed until 14 days p.i. 
IM administration exerted fluorescent signals until the end of 
the experiments showing the highest intensity when PNIPAM-
IR820-COOH post-synthesis was injected while the lowest 
signals were recorded for dye-labelled PLGA samples at the 
end of the study. When the materials were SC administered, 
the intensity of the signal after 14 days p.i. was intense in all 
mice being superior in both PNIPAM-IR820-COOH samples 
while the lowest were again displayed by dye-labelled PLGA-
treated experimental groups, which may be attributed to the 
lower proportion of PLGA label susceptible amine functional 
groups. Furthermore, the signals displayed an increase after 24 
h p.i. in SC administrations and also in IM PNIPAM-IR820-
COOH post-synthesis and PNIPAM-IR820 microgels due to the 
well-known binding between the dye and albumin in serum,47 
which probably was also displayed by the other experimental 
groups though their lower signals hid this increase, and 
subsequently did not correlate with the dye concentration
Figure 3 In vivo time course fluorescence imaging of labelled materials after intramuscular injection. All signals are presented 
according to the same color scale. a) PLGA-IR820 encapsulated; b) PLGA-IR820-NH2; c) PNIPAM-IR820-COOH; d) PNIPAM-IR820-
COOH post synthesis; e) PNIPAM-IR820 microgels; f) PNIPAM-IR820 microparticles.
target tissue, and consequently reducing potentially harmful 
side effects. The high biocompatibility and the long tracing of 
drug-carrying materials highlight the potential of these dye-
labelled materials for the safe and controlled delivery of drugs 
avoiding the direct labelling of drugs since unwanted chemical 
modifications of the drug could be produced impairing its 
activity. 
Previous studies have shown the formulation of NPs of D-
luciferin and NPs of DiR together with D-luciferin for in vivo 
tracking of NPs in tumour treatment.6 These lipid-based 
materials showed particle sizes lower than 200 nm and 
allowed the visualization of tumours more than 24 h, providing 
long-term tumours visualization though significantly lower 
than the time points revealed in our studies in which IM and
administer the therapeutic dose circumventing recurrent 
administrations and side effects. Local and targeted delivery of 
encapsulated drugs mediated by micro- and nanomaterials 
may increase stability and decrease clearance leading to safer 
and improved biomedical outcomes. The labelling of these 
engineered materials to successfully determine their 
biodistribution is an important step for the deeper knowledge 
of their behaviour and potential effects. In this study, we have 
proposed a successfully labelling of polymeric micro- and 
nanomaterials based on PLGA and PNIPAM with the NIR dye 
IR-820. Both the fluorescent probe and the polymers were 
modified in order to show that widely used polymeric 
materials of different sizes could be labelled for an efficient 
tracking in vivo. Local administration of drugs was developed 
to improve the efficacy of a drug being placed directly in the 
Figure 4 In vivo time course fluorescence imaging of labelled materials after subcutaneous injection. All signals are presented 
according to the same color scale. a) PLGA-IR820 encapsulated; b) PLGA-IR820-NH2; c) PNIPAM-IR820-COOH; d) PNIPAM-IR820-
COOH post synthesis; e) PNIPAM-IR820 microgels; f) PNIPAM-IR820 microparticles. 
 
labelled and tracked in a mice in vivo model after IV 
administration showing fluorescence signal until the end of the 
experiments (15 days p.i.), although recording again NP 
accumulation in the liver.51 Calcium phosphate NPs were 
loaded with silk sericin for the development of a new 
antitumor approach.52 Then, they were labelled with the NIR 
dye DiR by post-synthesis addition in order to track their 
biodistribution in a tumour mice model in which those dye-
labelled NPs were administered intravenously. The 
biodistribution was tracked by IVIS showing that NPs were 
mostly found in the liver and most of them were also degraded 
within two weeks. Furthermore, only a low percentage of NPs 
were localized in the tumour site, pointing to the need of more 
targeted and safer therapeutic strategies as we propose here. 
 SC administration displayed fluorescent signals after 7 and 14 
days, respectively (Figures 3 and 4). 
Other materials have also been labelled for bioimaging and 
biomedical applications, such as silica NPs50,51 or calcium 
phosphate NPs.52 Silica NPs bearing rhodamine B
isothiocyanate (20 or 100 nm), positively or negatively charged 
to elude the dissociation of the tracer, were orally 
administered to mice and fluorescence recorded in vivo up to 6 
h50. These studies highlighted the same in vivo behaviour of 
both charged NP types in spite of showing different sizes. Their 
systemic administration produced an accumulation in lung, 
kidney and liver, which is not advisable for therapeutic 
strategies in which more site-specific and efficient vectors and 
administrations are strongly encouraged. In this regard, other 
silica modified NPs (20-25 nm) were also covalently NIR 
Figure 5 Histological analysis after 7 days (IM) and 14 days (SC) post-injection. a) PNIPAM-IR820 MPs SC injection. Normal 
histologic features at epidermis, dermis, subcutaneous tissue and musculature, HE 10x; b) PNIPAM-IR820-COOH post-synthesis 
IM injection. Subcutaneous musculature (longitudinal section). No inflammatory infiltrate is observed between the muscle fibres, 
myocytes nuclei are well positioned and the fibres aligned, HE 20x; c) PLGA-IR820 encapsulated IM injection. Subcutaneous 
musculature (cross section). No degeneration or inflammatory lesions at the muscle fibres were observed, HE 20x; d) PNIPAM-
IR820 microgels SC injection. Popliteal lymph node. Note preservation of the ratio cortical/medullary thickness, HE 10x. 
of its ester bond into acidic monomers, facilitating its 
elimination from the organism through the endogenous 
metabolic pathways. However, its persistence in tissue has 
been recorded at long time points showing its presence after 
28 days post-implantation of PLGA scaffolds in a mice model.33 
These studies showed the decrease in the PLGA molecular 
weight to almost the half of the original one by the end of the 
experiments and recorded lower cell mobilization and 
angiogenesis than poly ε-caprolactone-based scaffolds, 
sustaining the unfavourable environment generated by the 
acidic monomers released during PLGA degradation, which 
was not observed in our studies as no harmful tissue reaction 
was observed even though at shorter time points. In this 
regard, PLGA-derived depots were fabricated as insulin 
reservoirs and SC administered in a diabetic murine model55 or 
as different therapeutic drug depots IM injected to rabbits56 
Liposomes (~200 nm) encapsulating a NIR dye (XenoFluor™-
680) and conjugated with a collagen antibody have been 
successfully tested in the early diagnosis of osteoarthritis in a 
murine in vivo model, achieving the visualization of affected 
joints by IVIS.53 However, the presence of those liposomes in 
other tissues different than knee cartilage was shown in spite 
of the retro-orbital administration. The esterification of PLGA 
to obtain polymers modified with nanocrystals has also been 
developed with diagnostic purposes.54 Gold nanocrystals and 
quantum dots were added to the polymer to yield 
diagnostically active lipid-PLGA NPs (~100 nm), which were 
detected in an in vitro model of mouse macrophages by IVIS 
though their biocompatibility or their efficiency in vivo were 
not disclosed.
PLGA has been widely used as nanocarrier or depot thanks to 
its high biocompatibility as it is degraded by simple hydrolysis
Figure 6 Histological study of the persistence of not-labelled PNIPAM MPs in tissue after injection. a) Macroscopic image of a 
BALB/c nu/nu mouse. Note the white foreign material (circle) located at the left hindlimb consistent with PNIPAM MPs; b) Well-
circumscribed fibrous encapsulation of foreign material at subcutaneous musculature. Moderate amount of fibroblasts and 
macrophages surrounding the eosinophilic amorphous material, HE 10x; c) Foreign body reaction is manly formed by foamy 
macrophages, giant cells and spindle-shaped active fibroblasts, HE 40x; d) The number of lymphocytes is increased expanding in 
the paracortical area. Lymphocytes are mature, small, normal in appearance and within their respective compartments 
characteristic of lymphoid hyperplasia, HE 10x; e) Blue staining indicating fibroplasia phenomena with formation of collagen  
fibres surrounding the foreign material,  Masson's  trichrome  stain  40x. 
penetrability and adhesion to tissue mucus. In this sense, NIR 
labelled (DY-675 and DY-700) PLGA NPs (~200 nm) were 
imaged after IV injection in murine models.59,60 Their efficiency 
was shown, even when only 1% of the labelled polymer was 
used to prepare the tagged NPs,60 but biodistribution was only 
acquired for short periods of time (≤ 24h) and NP 
accumulation in lungs and/or liver was registered, so their 
suitability for long term tracing and biomedical applications 
was not clearly confirmed. Furthermore, PLGA and PLGA-
PLA:PEG (poly(lactide)-poly(ethilene glycol)) nanospheres were 
and rats57, achieving a sustained release up to 16 days, 
highlighting their suitability as long-term effective reservoirs. 
In addition, the local delivery of PLGA NPs (~150-170 nm) 
labelled with coumarin-6 for IVIS imaging was tested in an 
intravaginal mice model in order to study the feasibility of 
these nanomaterials for intravaginal and local drug delivery.58 
Their efficiency as imaging vector was shown though only for 
24 h after administration and their potential delivery was 
higher when they were functionalized with PEG or avidin 
palmitate, due to their lower leakage related to their 
lymphadenopathies were observed either. PNIPAM MPs 
exerted a long-term persistence in tissues after 60 days 
without showing remarkable harmful effects. These results 
clearly pinpoint to the potential use of our novel labelled 
micro- and nanomaterials for the safe and localized drug 
delivery as well as to the suitability of PNIPAM as a long-term 
drug carrier. The determination of drugs in physiological fluids 
(blood, urine, etc.) or in tissues can be challenging and, for that 
reason, tracking their encapsulating carriers might help when 
explaining the medical outcome of the drug treatment without 
the need of drug radiolabeling or using time-consuming 
chromatographic methods. 
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